ALXN-1850
- Generic Name
- ALXN-1850
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Phase 3
Active, not recruiting
- Conditions
- Hypophosphatasia
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06079372
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06079281
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06079359
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04980248
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath